Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 887 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GBM Patients Clear all
Completed Phase 1 Interventional

Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

NCT03452930
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Radiation Therapy, Tinostamustine
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Early Phase 1 Interventional

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

NCT01091792
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Bevacizumab
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02667587
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
Drug · Radiation · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

NCT00402116
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
Interventions
enzastaurin, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 10, 2026, 4:38 AM EDT
Withdrawn Phase 2 Interventional

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

NCT03014804
View directory record Official record
Conditions
Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
Interventions
autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT01806675
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Hypopharyngeal Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Laryngeal Cancer, Recurrent Lip and Oral Cavity Cancer, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Nasopharyngeal Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Oropharyngeal Cancer, Recurrent Pancreatic Cancer, Recurrent Paranasal Sinus and Nasal Cavity Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Colon Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer, Tongue Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
Drug
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Not applicable Interventional Results available

Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom

NCT05140902
View directory record Official record
Conditions
Glioblastoma
Interventions
Point-of-care Portable Perfusion Phantom (P4)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 2 Interventional

Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01591577
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma Multiforme
Interventions
Lapatinib/Temozolomide/radiation
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 2 Interventional

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00305656
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
cediranib maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 10, 2026, 4:38 AM EDT
Terminated Phase 1 Interventional Results available

First in Patient Study for PF-06840003 in Malignant Gliomas

NCT02764151
View directory record Official record
Conditions
Oligodendroglioma, Astrocytoma, Malignant Glioma
Interventions
PF-06840003
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Los Angeles, California • Boston, Massachusetts • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Results available

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

NCT00813943
View directory record Official record
Conditions
Glioblastoma
Interventions
Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

NCT02067156
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Not applicable Interventional Results available

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

NCT02410577
View directory record Official record
Conditions
Glioblastoma
Interventions
89Zr-J591, PET/CT Scan, MRI, Blood draw
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
26 Years to 79 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Results available

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

NCT00612430
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab and Etoposide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 10, 2026, 4:38 AM EDT
Terminated Not applicable Interventional Results available

MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma

NCT00756106
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, Imaging biomarker analysis, Photon Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 10, 2026, 4:38 AM EDT
Recruiting Phase 2 Interventional

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

NCT05864534
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
Interventions
Balstilimab, Botensilimab, Liposomal Doxorubicin, Sonocloud-9 (SC-9)
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 10, 2026, 4:38 AM EDT
Completed No phase listed Observational

Study of Tissue and Blood Samples From Patients With High-Grade Glioma

NCT01004887
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
diagnostic laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2019
U.S. locations
110
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00553150
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
everolimus, temozolomide, radiation
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
178
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 115 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Sep 10, 2026, 4:38 AM EDT
Recruiting Phase 2 Interventional

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

NCT07708961
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 1 Interventional

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

NCT00979862
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 1Phase 2 Interventional

ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma

NCT00352313
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
ATN-161, carboplatin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Sep 10, 2026, 4:38 AM EDT
Suspended No phase listed Observational

Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma

NCT04657146
View directory record Official record
Conditions
Glioblastoma
Interventions
Biorepository
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 10, 2026, 4:38 AM EDT
Completed Phase 2 Interventional

Suramin in Treating Patients With Recurrent Primary Brain Tumors

NCT00002639
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
chemotherapy, suramin
Drug
Lead sponsor
Emory University
Other
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 10, 2026, 4:38 AM EDT